Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Drug Photosensitivity: Clinical Features, Diagnosis, Common Culprits, and Management
Description
The presentation reviewed drug photosensitivity, focusing mainly on systemic phototoxicity rather than photoallergy. It explained that phototoxic reactions occur when a drug or its metabolite in the skin is activated by light, usually UVA, causing oxidative damage; susceptibility may relate to genetic factors and drug properties such as low molecular weight or aromatic halogens. Drug photosensitivity is not rare in photobiology clinics, and the most common presentation is a sunburn-like reaction with immediate burning or prickling on sun exposure, though eczematous eruptions, lichenoid drug eruptions, drug-induced lupus, phototelangiectasia, pigmentation changes, photoonycholysis, pseudoporphyria, and photocarcinogenesis can also occur. Common culprits include thiazide diuretics, tetracyclines, quinine, NSAIDs, amiodarone, voriconazole, calcium channel blockers, azathioprine, BRAF inhibitors, PPIs, terbinafine, TNF-alpha antagonists, and hydrochlorothiazide, with some drugs associated with increased skin cancer risk. Diagnosis relies on a detailed medication history, the timing of symptoms, and phototesting, especially because drug photosensitivity typically shows UVA sensitivity. Management involves stopping or switching the culprit drug when possible, recognizing that symptoms may persist for months after discontinuation, and otherwise emphasizing UVA-protective sunscreen and physical photoprotection. The talk highlighted that accurate diagnosis can significantly improve quality of life because this is often a reversible cause of photosensitivity.
View moreConclusions
- Drug photosensitivity is most often a phototoxic, rather than photoallergic, reaction and usually presents as a sunburn-like eruption with burning or prickling on sun exposure.
- Most clinically important drug photosensitivity reactions are driven primarily by UVA, so a detailed drug history and UVA-focused phototesting are key diagnostic tools.
- Only a minority of exposed patients develop photosensitivity, suggesting that host factors such as genetics, metabolism, and transport pathways influence susceptibility.
- Drug photosensitivity can mimic several patterns including eczematous, lichenoid, lupus-like, telangiectatic, dyspigmented, pseudoporphyric, and photo-onycholytic eruptions.
- Common culprit drugs include thiazides, tetracyclines, quinine, NSAIDs, amiodarone, voriconazole, calcium channel blockers, azathioprine, and some biologics.
- Certain medications may also be linked to increased photocarcinogenesis and skin cancer risk, especially with chronic exposure or in immunosuppressed patients.
- The diagnosis is often challenging in polypharmacy, but a strong temporal relationship between medication start and photosensitivity symptoms is a major clue.
- Phototesting is helpful but not definitive, because some affected patients may have normal minimal erythema doses despite true drug photosensitivity.
- Drug photosensitivity can substantially impair quality of life, but it is potentially reversible if recognized and managed promptly.
- Management centers on stopping or switching the culprit drug when possible, and otherwise on strict photoprotection with broad-spectrum UVA coverage and physical sun avoidance.
- Ibbotson, Photochem Photobiol Sci 2018
- Egberts et al. Pharmacoepidemiol Drug Saf 2009;18:602–609
- Ahad et al. Photodermatol Photoimmunol Photomed. 2020
- Ammoury A et al, Arch Dermatol. 2008;144(1):92–96
- Ahad et. al. Photodermatol Photoimmunol Photomed. 2020 36:441-451
- Ahad et. al. Photodermatol Photoimmunol Photomed 2020;36:441–451